Market revenue in 2024 | USD 36.1 million |
Market revenue in 2030 | USD 31.0 million |
Growth rate | -2.9% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 58.17% in 2024. Horizon Databook has segmented the Saudi Arabia anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Saudi Arabia’s market is projected to witness significant growth over the forecast period, owing to an increase in government initiatives. An article suggested that in 2017, AMD accounted for 3.3% of blindness cases in individuals older than 50 years. To address the unmet needs of population, the Ministry of Health approved funding for construction of additional tertiary eye care hospitals in 2014.
Furthermore, favorable government initiatives may help support market growth. Under the National Transformation Program, the Ministry of Health invested around USD 71 billion in 5 years. Moreover, 15.6% of the 2019 budget was allocated to healthcare, which may contribute to the growth of market in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account